Contrasting Bioqual (OTCMKTS:BIOQ) & Daxor (NASDAQ:DXR)

Bioqual (OTCMKTS:BIOQ) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings for Bioqual and Daxor, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioqual	0	0	0	0	0.00
Daxor	0	1	1	0	2.50

Daxor has a consensus price target of $25.00, suggesting a potential upside of 98.26%. Given Daxor’s stronger consensus rating and higher probable upside, analysts plainly believe Daxor is more favorable than Bioqual.

Valuation and Earnings

This table compares Bioqual and Daxor”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioqual	$48.87 million	0.73	-$1.05 million	($1.18)	-33.90
Daxor	N/A	N/A	N/A	N/A	N/A

Daxor has lower revenue, but higher earnings than Bioqual.

Insider & Institutional Ownership

1.3% of Daxor shares are held by institutional investors. 39.2% of Bioqual shares are held by company insiders. Comparatively, 59.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Bioqual and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioqual	-2.14%	-2.90%	-1.87%
Daxor	N/A	N/A	N/A

Risk and Volatility

Bioqual has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.

Summary

Daxor beats Bioqual on 9 of the 10 factors compared between the two stocks.

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.